Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Christie P. M. Verkleij"'
Autor:
Charlotte L. B. M. Korst, Kaz Groen, Patricia W. C. Bosman, Fleur van derValk, Christie P. M. Verkleij, Sandy Kruyswijk, Maaike E. M. deRuijter, Dianne M. Heijink, Maria T. Kuipers, Sonja Zweegman, Niels W. C. J. van deDonk
Publikováno v:
HemaSphere, Vol 8, Iss 7, Pp n/a-n/a (2024)
Externí odkaz:
https://doaj.org/article/3a95234d406b4ae6bd0201b04fb42ff2
Publikováno v:
Hemato, Vol 2, Iss 1, Pp 116-130 (2021)
In the 2010s, immunotherapy revolutionized the treatment landscape of multiple myeloma. CD38-targeting antibodies were initially applied as monotherapy in end-stage patients, but are now also approved by EMA/FDA in combination with standards-of-care
Externí odkaz:
https://doaj.org/article/33c01c8ea07e4041822f5d012e1e2948
Autor:
Pieter Langerhorst, Joannes F M Jacobs, Martijn M. VanDuijn, Christie P. M. Verkleij, Marina Zajec, Yolanda B. de Rijke, Somayya Noori, Patricia W. C. Bosman, Sonja Zweegman, Theo M. Luider, Niels W.C.J. van de Donk
Publikováno v:
Clinical Chemistry and Laboratory Medicine, 59(12), 1963-1971. De Gruyter
Noori, S, Verkleij, C P M, Zajec, M, Langerhorst, P, Bosman, P W C, de Rijke, Y B, Zweegman, S, Vanduijn, M, Luider, T, van de Donk, N W C J & Jacobs, J F M 2021, ' Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: The laboratory solution to eliminate interference ', Clinical Chemistry and Laboratory Medicine, vol. 59, no. 12, pp. 1963-1971 . https://doi.org/10.1515/cclm-2021-0399
Clinical Chemistry and Laboratory Medicine, 59, 12, pp. 1963-1971
Clinical Chemistry and Laboratory Medicine, 59, 1963-1971
Clinical Chemistry and Laboratory Medicine, 59(12), 1963-1971. Walter de Gruyter GmbH
Noori, S, Verkleij, C P M, Zajec, M, Langerhorst, P, Bosman, P W C, de Rijke, Y B, Zweegman, S, Vanduijn, M, Luider, T, van de Donk, N W C J & Jacobs, J F M 2021, ' Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: The laboratory solution to eliminate interference ', Clinical Chemistry and Laboratory Medicine, vol. 59, no. 12, pp. 1963-1971 . https://doi.org/10.1515/cclm-2021-0399
Clinical Chemistry and Laboratory Medicine, 59, 12, pp. 1963-1971
Clinical Chemistry and Laboratory Medicine, 59, 1963-1971
Clinical Chemistry and Laboratory Medicine, 59(12), 1963-1971. Walter de Gruyter GmbH
Objectives The therapeutic monoclonal antibody (t-mAb) daratumumab, used to treat multiple myeloma (MM) patients, interferes with routine, electrophoretic based M-protein diagnostics. Electrophoretic response assessment becomes increasingly difficult
Publikováno v:
Hemato, Vol 2, Iss 7, Pp 116-130 (2021)
In the 2010s, immunotherapy revolutionized the treatment landscape of multiple myeloma. CD38-targeting antibodies were initially applied as monotherapy in end-stage patients, but are now also approved by EMA/FDA in combination with standards-of-care
Publikováno v:
Current Opinion in Oncology, 32(6), 664-671. Lippincott Williams and Wilkins
Verkleij, C P M, Korst, C L B M & van de Donk, N W C J 2020, ' Immunotherapy in multiple myeloma : when, where, and for who? ', Current Opinion in Oncology, vol. 32, no. 6, pp. 664-671 . https://doi.org/10.1097/CCO.0000000000000677
Verkleij, C P M, Korst, C L B M & van de Donk, N W C J 2020, ' Immunotherapy in multiple myeloma : when, where, and for who? ', Current Opinion in Oncology, vol. 32, no. 6, pp. 664-671 . https://doi.org/10.1097/CCO.0000000000000677
PURPOSE OF REVIEW: Immunotherapy is transforming treatment of multiple myeloma patients in all stages of their disease. This review will discuss recent developments in immunotherapy in multiple myeloma with a focus on antibodies, antibody-drug conjug
Autor:
Saskia K. Klein, Gerard M. J. Bos, Sonja Zweegman, Mark-David Levin, Niels W.C.J. van de Donk, Kristine A. Frerichs, Monique C. Minnema, Marie José Kersten, Annemiek Broijl, Inger S. Nijhof, Tuna Mutis, Pieter Sonneveld, Patty W C Maas-Bosman, Christie P. M. Verkleij
Publikováno v:
Blood advances, 5(23), 5128-5139. American Society of Hematology
Blood, 5, 5128-5139. American Society of Hematology
Blood advances, 5, 5128-5139. American Society of Hematology
Blood Advances, 5, 5128-5139. AMER SOC HEMATOLOGY
Blood advances, 5(23), 5128-5139. The American Society of Hematology
Frerichs, K A, Minnema, M C, Levin, M-D, Broijl, A, Bos, G M J, Kersten, M J, Mutis, T, Verkleij, C P M, Nijhof, I S, Maas-Bosman, P W C, Klein, S K, Zweegman, S, Sonneveld, P & van de Donk, N W C J 2021, ' Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma ', Blood, vol. 5, pp. 5128-5139 . https://doi.org/10.1182/bloodadvances.2021005220
Blood, 5, 5128-5139. American Society of Hematology
Blood advances, 5, 5128-5139. American Society of Hematology
Blood Advances, 5, 5128-5139. AMER SOC HEMATOLOGY
Blood advances, 5(23), 5128-5139. The American Society of Hematology
Frerichs, K A, Minnema, M C, Levin, M-D, Broijl, A, Bos, G M J, Kersten, M J, Mutis, T, Verkleij, C P M, Nijhof, I S, Maas-Bosman, P W C, Klein, S K, Zweegman, S, Sonneveld, P & van de Donk, N W C J 2021, ' Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma ', Blood, vol. 5, pp. 5128-5139 . https://doi.org/10.1182/bloodadvances.2021005220
The efficacy of daratumumab depends partially on CD38 expression on multiple myeloma (MM) cells. We have previously shown that all-trans retinoic acid (ATRA) upregulates CD38 expression and reverts daratumumab-resistance ex vivo. We therefore evaluat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1300c789f6fb8b2ff67d082a73870fc2
https://pure.eur.nl/en/publications/27f5b501-5187-486c-80a3-6a54af2e2834
https://pure.eur.nl/en/publications/27f5b501-5187-486c-80a3-6a54af2e2834
Autor:
Mashhour Hosny, Sonja Zweegman, Christie P. M. Verkleij, Kristine A. Frerichs, Niels W.C.J. van de Donk, Jort J. van der Schans, Tuna Mutis
Publikováno v:
Hosny, M, Verkleij, C P M, van der Schans, J, Frerichs, K A, Mutis, T, Zweegman, S & van de Donk, N W C J 2021, ' Current state of the art and prospects of t cell-redirecting bispecific antibodies in multiple myeloma ', Journal of Clinical Medicine, vol. 10, no. 19, 4593 . https://doi.org/10.3390/jcm10194593
Journal of Clinical Medicine
Journal of Clinical Medicine, Vol 10, Iss 4593, p 4593 (2021)
Journal of Clinical Medicine
Journal of Clinical Medicine, Vol 10, Iss 4593, p 4593 (2021)
Multiple myeloma (MM) patients eventually develop multi-drug-resistant disease with poor survival. Hence, the development of novel treatment strategies is of great importance. Recently, different classes of immunotherapeutic agents have shown great p
Autor:
Tuna Mutis, Sonja Zweegman, Meletios A. Dimopoulos, Mary H. Young, Kristine A. Frerichs, Christie P. M. Verkleij, Kathryn Newhall, Jhon A. Marin Soto, Niels W.C.J. van de Donk
Publikováno v:
Cancers, Vol 13, Iss 2452, p 2452 (2021)
Cancers
Frerichs, K A, Verkleij, C P M, Dimopoulos, M A, Marin Soto, J A, Zweegman, S, Young, M H, Newhall, K J, Mutis, T & van de Donk, N W C J 2021, ' Efficacy and safety of durvalumab combined with daratumumab in daratumumab-refractory multiple myeloma patients ', Cancers, vol. 13, no. 10, 2452 . https://doi.org/10.3390/cancers13102452
Cancers, 13(10):2452. Multidisciplinary Digital Publishing Institute (MDPI)
Volume 13
Issue 10
Cancers
Frerichs, K A, Verkleij, C P M, Dimopoulos, M A, Marin Soto, J A, Zweegman, S, Young, M H, Newhall, K J, Mutis, T & van de Donk, N W C J 2021, ' Efficacy and safety of durvalumab combined with daratumumab in daratumumab-refractory multiple myeloma patients ', Cancers, vol. 13, no. 10, 2452 . https://doi.org/10.3390/cancers13102452
Cancers, 13(10):2452. Multidisciplinary Digital Publishing Institute (MDPI)
Volume 13
Issue 10
Simple Summary The CD38-targeting antibody daratumumab has marked activity in multiple myeloma through direct anti-tumor effects and immunomodulatory activity. However, eventually most patients will develop daratumumab-refractory disease. We hypothes
Autor:
Martin Kaiser, Pieter Sonneveld, Jocelyn Sendecki, Kristine A. Frerichs, Rowan Kuiper, Amy Axel, Gareth J. Morgan, Rengasamy Boominathan, Mark van Duin, Homer Adams, Niels W.C.J. van de Donk, Sonja Zweegman, A. Vera de Jonge, Marloes E. C. Broekmans, Christie P. M. Verkleij, Raluca Verona, Tuna Mutis, Amy Wong
Publikováno v:
Blood, 5(8), 2196-2215. American Society of Hematology
Blood Adv
Blood advances, 5(8), 2196-2215. American Society of Hematology
Verkleij, C P M, Broekmans, M E C, van Duin, M, Frerichs, K A, Kuiper, R, de Jonge, A V, Kaiser, M, Morgan, G, Axel, A, Boominathan, R, Sendecki, J, Wong, A, Verona, R I, Sonneveld, P, Zweegman, S, Adams, H C, Mutis, T & van de Donk, N W C J 2021, ' Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma ', Blood, vol. 5, no. 8, pp. 2196-2215 . https://doi.org/10.1182/BLOODADVANCES.2020003805
Blood Adv
Blood advances, 5(8), 2196-2215. American Society of Hematology
Verkleij, C P M, Broekmans, M E C, van Duin, M, Frerichs, K A, Kuiper, R, de Jonge, A V, Kaiser, M, Morgan, G, Axel, A, Boominathan, R, Sendecki, J, Wong, A, Verona, R I, Sonneveld, P, Zweegman, S, Adams, H C, Mutis, T & van de Donk, N W C J 2021, ' Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma ', Blood, vol. 5, no. 8, pp. 2196-2215 . https://doi.org/10.1182/BLOODADVANCES.2020003805
Cell surface expression levels of GPRC5D, an orphan G protein–coupled receptor, are significantly higher on multiple myeloma (MM) cells, compared with normal plasma cells or other immune cells, which renders it a promising target for immunotherapeu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f03cce28d6591a67ad3c60851b3082d9
https://research.vumc.nl/en/publications/ff43680e-531e-497e-b269-e432bb5d0872
https://research.vumc.nl/en/publications/ff43680e-531e-497e-b269-e432bb5d0872
Autor:
Saskia K. Klein, Marie José Kersten, Christie P. M. Verkleij, Sonja Zweegman, Pieter Sonneveld, Annemiek Broyl, Niels W.C.J. van de Donk, Mark-David Levin, Patricia W. C. Bosman, Gerard M. J. Bos, Kristine A. Frerichs, Monique C. Minnema, Tuna Mutis
Publikováno v:
Blood, 134. American Society of Hematology
Frerichs, K A, Minnema, M C, Levin, M-D, Broyl, A, Bos, G, Kersten, M J, Mutis, T, Verkleij, C P M, Bosman, P W C, Klein, S K, Zweegman, S, Sonneveld, P & Van de Donk, N W C J 2019, ' Efficacy and Safety of Daratumumab Combined with All-Trans Retinoic Acid in Relapsed/Refractory Multiple Myeloma; Results of the Phase 1/2 Dara/ATRA Study ', Blood, vol. 134 . https://doi.org/10.1182/blood-2019-123383
Frerichs, K A, Minnema, M C, Levin, M-D, Broyl, A, Bos, G, Kersten, M J, Mutis, T, Verkleij, C P M, Bosman, P W C, Klein, S K, Zweegman, S, Sonneveld, P & Van de Donk, N W C J 2019, ' Efficacy and Safety of Daratumumab Combined with All-Trans Retinoic Acid in Relapsed/Refractory Multiple Myeloma; Results of the Phase 1/2 Dara/ATRA Study ', Blood, vol. 134 . https://doi.org/10.1182/blood-2019-123383
Introduction: Daratumumab (DARA) has potent single agent activity in relapsed/refractory multiple myeloma (RRMM). The effectivity of DARA is partially dependent on the expression of its target, CD38, on tumor cells. Upregulation of CD38 on MM cells b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d8f456643920f92042b538caa5931bd
https://research.vumc.nl/en/publications/94e5b22d-cf50-4781-b484-c23d4cf15c39
https://research.vumc.nl/en/publications/94e5b22d-cf50-4781-b484-c23d4cf15c39